Clinical Trial: An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07693608) titled 'An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder' on July 02.

Brief Summary: This open label pilot study will assess the feasibility and preliminary efficacy of tirzepatide which will be prescribed under its FDA approved weight management indication in adults with moderate or severe methamphetamine, cocaine or prescription stimulant use disorder (MUD) who also meet criteria for obesity or overweight with comorbidities. Up to 30 participants will receive 20 weeks of once weekly tirzepatide, followed by an observational follow up period.

The study also incorporates MRI at seven time points to explore ne...